DRNA US2530311081

End-of-day quote Nasdaq - 12/27
38.22	USD		+0.58%

2021	Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisition	MT
2021	Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk	MT
2021	DICERNA PHARMACEUTICALS, INC.(NASDAQGS : DRNA) dropped from S&P TMI Index	CI

Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Biotechnology Select Industry Index

12/30/2021 | 12:00am EDT

All news about DICERNA PHARMACEUTICALS, INC.

2021	Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..	MT
2021	Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..	MT
2021	DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index	CI
2021	DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..	CI
2021	DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index	CI
2021	Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition	MT
2021	DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..	PU
2021	DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..	AQ
2021	Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals	MT
2021	Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition	BU

Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.

2021	Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..	MT
2021	Chardan Downgrades Dicerna Pharmaceuticals to Neutral Rating From Buy on Proposed Acqui..	MT
2021	Chardan Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts Price Target to..	MT

Chart DICERNA PHARMACEUTICALS, INC.

Duration : Period :

Managers and Directors

Bob D. Brown	President
Shreeram Aradhye	Chief Medical Officer & Executive Vice President
James B. Weissman	Chief Operating Officer & Executive Vice President
Jamie Haney	Director
Ulrich Christian Otte	Director

Sector and Competitors

		1st jan.	Capi. (M$)
	DICERNA PHARMACEUTICALS, INC.	0.00%	2 986


GILEAD SCIENCES, INC.	-10.76%	81 280
REGENERON PHARMACEUTICALS, INC.	9.70%	74 647
VERTEX PHARMACEUTICALS	24.65%	70 008
BIONTECH SE	-35.24%	40 574
WUXI APPTEC CO., LTD.	-22.01%	39 958

DICERNA PHARMACEUTICALS, INC.